Navigation Links
Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2011 Results
Date:8/9/2011

f total revenue, research and development expenses increased to 7.3% for the second quarter of 2011 from 5.7% for the same period in 2010. For the first six months of 2011, research and development expenses totaled RMB82.7 million (US$12.8 million), compared to RMB61.8 million for the same period in 2010.

Sales, marketing and distribution expenses for the second quarter of 2011 were RMB288.9 million (US$44.6 million), which represented a decrease of 9.7% from RMB319.9 million for the same period in 2010. As a percentage of total revenue, sales, marketing and distribution expenses decreased to 52.9% for the second quarter of 2011 from 58.8% for the same period in 2010. This decrease was due primarily to the strengthened budget control and efficiency improvement on marketing activities. For the first six months of 2011, sales, marketing and distribution expenses were RMB553.2 million (US$85.5 million), which represented a decrease of 0.6% from RMB556.8 million for the same period in 2010.

General and administrative expenses were RMB74.7 million (US$11.5 million) for the second quarter of 2011, which represented an increase of 27.3% from RMB58.6 million for the same period in 2010. As a percentage of total revenue, general and administrative expenses increased to 13.7% for the second quarter of 2011 from 10.8% for the same period in 2010. This increase was due primarily to the increased salary expenses and legal fees incurred for establishing a joint venture with Merck & Co., Inc.. For the first six months of 2011, general and administrative expenses were RMB142.8 million (US$22.1 million), which represented an increase of 13.4% from RMB125.9 million for the same period in 2010.

Share-based compensation expenses, which were allocated to research and development expenses, sales, marketing and distribution expenses, and general and administrative
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
2. Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals
3. Simcere Pharmaceutical Group to Acquire Additional Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd.
4. Simcere Pharmaceutical Group Announces Jiangsu Yanshens Voluntary Suspension of Production
5. Simcere Pharmaceutical Group Provides Update on Jiangsu Yanshen
6. Simcere Receives SFDA Approval to Manufacture and Sell Zanamivir in China
7. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Tuesday, March 16, 2010
8. Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study
9. Simceres Diosmectite API Passes EU-GMP Inspection
10. Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results
11. Simcere Pharmaceutical Group Files Annual Report on Form 20-F
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: ... concerning composition of matter, biological targets, mechanism of action, ... This patent application describes a novel ... (VSRNAs) which interfere with the basic homeostatic cellular processes ...
(Date:1/15/2014)...  According to Millennium Research Group (MRG), the global ... the United States and European transcatheter ... moderately through 2022, with embolization particles representing one ... in drug-eluting beads (DEBs) and radioembolization spheres in ...
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
(Date:7/10/2014)... omega 3 fatty acids had healthier joints than those ... fatty acids, according to Duke Medicine researchers. , The ... Diseases (10.1136/annrheumdis-2014-205601) on July 11, 2014, suggest that ... contribute to worsening osteoarthritis. , "Our results suggest that ... factors in the link between obesity and osteoarthritis," said ...
(Date:7/10/2014)... July 10, 2014 One week ahead ... Worker Safety announced today it will extend compensation benefits ... months’ wages for workers displaced as a result of ... Alliance inspections have resulted in the closure of five ... five cases, raising immediate safety concerns. In May, the ...
(Date:7/10/2014)... 2014 Best Drug Rehabilitation ... having family close by during a stay in ... or not the process is successful, has launched ... at http://www.bestdrugrehabilitation.com/success-stories/ . , The new Success ... from several Best Drug Rehabilitation graduates who wanted ...
(Date:7/10/2014)... As the use of electronic health record becomes widespread ... implementation of the Affordable Care Act, the quantity of ... analytic purposes will also dramatically increase. Additionally, experts ... that analyze large quantities of data for the purpose ... the value of patient care a process that ...
(Date:7/10/2014)... HealthDay Reporter THURSDAY, July 10, ... hot flashes that often accompany menopause, new research suggests. ... of menopausal women, said Dr. Taraneh Shirazian, an assistant professor ... School of Medicine at Mount Sinai Hospital in New York ... hot flashes a day, and she added that hot flashes ...
Breaking Medicine News(10 mins):Health News:Omega 3 fatty acids lessen severity of osteoarthritis in mice 2Health News:Alliance for Bangladesh Worker Safety to Double Compensation for Displaced Factory Workers; Members Vote to Extend Wage Benefits from Two to up to Four Months 2Health News:Best Drug Rehabilitation Launches New Success Stories Section of Website 2Health News:Six cases where big data can reduce healthcare costs 2Health News:Six cases where big data can reduce healthcare costs 3Health News:Six cases where big data can reduce healthcare costs 4Health News:Losing Weight May Ease Hot Flashes, Study Finds 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 3
... Coaches, trainers focus on prevention, better treatment for ... -- "Getting your bell rung." "A dinger." "Knocking ... a serious problem -- a concussion. , But ... are getting a lot better at spotting a ...
... barometer - gas prices go up, major ... market trend to stay home, shop online, REDMOND, Wash., ... offering over 30,000 supplements at,savings up to 50% today announced that ... quarters of 2008 as people change shopping habits to,offset today,s high ...
... Holmes,(Amex: HH ) today announced the sale ... Claims Evaluation Division (CED), a unit providing,independent medical ... for use in evaluating claims., The sale ... purchase,price of approximately $5.6 million. In one transaction, ...
... prices, biofuels, and climate change places 1.7,billion people ... risk of hunger, warns,anti-poverty agency ActionAid., WASHINGTON, ... in Hokkaido, Japan, ActionAid launches a new report, ... Global Food Crisis and What,They Can Do to ...
... NavigatorMD, Inc., a leading,benefits intelligence, software ... of Value-Based Plan Design development, announced,the addition ... Development and,Sales., Norris brings 24 years ... including market development and management. As Director ...
... - Thyroid cancer that has spread to distant sites has ... blood vessel formation can slow disease progression in some patients, ... Texas M. D. Anderson Cancer Center reports in the July ... . , The investigational drug, motesanib diphosphate, is a VEGF ...
Cached Medicine News:Health News:Playing It Safe With High School Sports 2Health News:Playing It Safe With High School Sports 3Health News:Playing It Safe With High School Sports 4Health News:Photo: VitaminLife.com Sees Internet Sales Up 40% in Major Metro Markets as Gas Crisis Looms; Shopping Behaviors Change as People Conserve Gas 2Health News:Hooper Holmes Announces Sale of Claims Evaluation Division 2Health News:ActionAid Challenges G8 on Response to Food Crisis 2Health News:Marshall Norris Joins NavigatorMD as Director of Business Development and Sales 2Health News:Blood vessel inhibitor shows promise against metastatic thyroid cancer 2Health News:Blood vessel inhibitor shows promise against metastatic thyroid cancer 3Health News:Blood vessel inhibitor shows promise against metastatic thyroid cancer 4
Contrast sensitivity testing, glare sensitivity testing and ETDRS acuity testing are provided in the self standardized CSV-1000 instrument. Patented photocell circuitry automatically monitors and cal...
The Wills Eye Manual, Fourth Edition has been updated to include the newest drugs, procedures, and treatment protocols. Clinicians will have instant access to current information on diagnosis and tre...
... Reviews enable all those involved with healthcare ... the very latest evidence in their field ... harder each year as the volume of ... by delivering the best single source available ...
Muscles Anatomy Flash Cards uses the time tested content and images from BryanEdwards.com....
Medicine Products: